With increased adherence, the Company believes that patients with existing chronic conditions can better manage their health and prevent the onset of co-morbid conditions while facilitating a reduction in healthcare costs.
Company to Leverage Precise Biometrics and Actionable Feedback to Improve Chronic Disease Care and Reduce Healthcare Costs
REDWOOD CITY, Calif., Jan. 26, 2018 (GLOBE NEWSWIRE) -- Biotricity (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company dedicated to delivering innovative, biometric remote monitoring solutions, is poised to change cardiac healthcare into a preventive and cost-savings model that leverages precise biometrics and actionable feedback to motivate patient adherence. With increased adherence, the Company believes that patients with existing chronic conditions can better manage their health and prevent the onset of co-morbid conditions while facilitating a reduction in healthcare costs.
Biotricity is developing a spectrum of real-time and high-precision remote patient monitoring solutions (RPM). The company’s premier product, Bioflux, is a high-precision, single-unit mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of ambulatory patients’ ECG information.
With shorter time gaps between follow-up appointments, RPM devices can increase patient adherence by shortening the feedback loop and enabling patients to take the necessary action to mitigate negative health outcomes.
“When patients can track their progress, and see how certain choices have a direct and positive impact on their health, they are more likely to adhere to treatment plans, engage in their healthcare, and change their behavior,” said Waqaas Al Siddiq, Biotricity Founder and CEO.
This kind of proactive approach to healthcare should also lead to a reduction in healthcare costs, both for patients and providers. Chronic conditions necessitate the kind of minute diligence and around-the-clock monitoring that an RPM device can offer; attempting to provide comparative in-facility care for chronic conditions only places an undue burden on an already over-taxed healthcare system. Many patients struggle to find the resources to visit a physician’s office for frequent and routine checkups, which an RPM device could provide accurately and conveniently at home. Biotricity’s development strategy for its RPM solutions is focused on enabling physicians and healthcare providers to receive reimbursement by using existing CPT codes to bill for the company’s solutions.
To learn more, visit www.biotricity.com or follow on
Twitter: @biotricity_inc Facebook: facebook.com/biotricity/ or
LinkedIn: linkedin.com/company/biotricity-measuring-vitals
About Biotricity Inc.
Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Media Contacts
McCoin & Smith Communications Inc.
Chris McCoin,
Chris@mccoinsmith.com, 508-429-5988
Richard Smith,
rick@mccoinsmith.com, 978-433-3304
Investor Relations:
Biotricity Inc.
1-800-590-4155
investors@biotricity.com
